X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Aptevo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
ALG.APV-527 is a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4. This has the potential to stimulate the immune cells involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
ALG.APV-527 is a bispecific conditional 4-1BB agonist, actuvates upon simultaneous binding to 4-1BB and 5T4. 4-1BB has the ability to stimulate the antitumor-specific T cells and NK cells and 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aptevo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
ADC-1013 (Mitazalimab) is an agonistic/stimulatory antibody that targets and activates CD40 (receptor on the dendritic cells of the immune system), enabling dendritic cells to stimulate the immune response’s weapons more effectively to attack the cancer selectively.
Lead Product(s): Mitazalimab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2023
Details:
Alligator out-licensed AC101 (HLX22) to the South Korean company AbClon, Inc. in 2016, who sub-licensed the drug candidate to Henlius Biotech for clinical and commercial development in China.
Lead Product(s): HLX22,Serplulimab,Trastuzumab
Therapeutic Area: Oncology Product Name: AC101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
The Data Review Committee has declared the 900 µg/kg mitazalimab, an agonistic or stimulatory antibody that targets CD40 dose to be safe and recommended that the dosing level should be continued for the Phase II study.
Lead Product(s): Mitazalimab,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
The sponsored research collaboration will support the UPENN study, a part of Alligator’s OPTIMIZE-1 clinical trial, multi-center phase 1B/I I trial assessing the clinical efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic cancer.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Pennsylvania
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2022
Details:
ADC-1013 (mitazalimab), a CD40 agonist reported no adverse event at dosed of 450 µg/kg cohort in combination with mFOLFIRINOX for treatment of pancreatic ductal adenocarcinoma in OPTIMIZE-1 Phase Ib/II trial.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
Under the agreement, Alligator Bioscience will employ its proprietary phage display libraries and RUBY™ bispecific platform to develop immuno-oncology product candidates based on design criteria identified by Orion.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orion Pharma
Deal Size: $552.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 18, 2021
Details:
The abstract shows that mitazalimab effectively enhances the effects of chemotherapy, especially with FOLFIRINOX, leading to improved long-term survival in a preclinical tumor model.
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
